In this episode, we hear from Sean Khozin, Senior Partner at the investment firm Braven Partners. He focuses on advancing in innovations at the intersection of biology, technology and AI. Sean was previously the CEO of CancerLinQ and the Global Head of Data Strategy and Data Science at Johnson & Johnson. He had a successful tenure in the US federal government as the associate director of FDA’s Oncology Center of Excellence and the founding executive director of FDA INFORMED, a data science and technology incubator he established under special authorities from the US department of health and human services.
Topics include:
How are Braven Partners incubating and supporting minimally viable ecosystems of companies that can make a difference?
What are the goals of the Alliance for Artificial Intelligence in Healthcare?
How can digital therapeutics developers ensure effective reimbursement for their products in the healthcare industry?
How is the ethos of AI in healthcare speaking to a culture that is focused on safety without compromising innovation?
How do we demystify new tools and technologies such as AI?
How does the FDA think about regulating AI?
What can digital therapeutic manufacturers companies, entrepreneurs and trailblazers learn from the Alliance for Artificial Intelligence in Healthcare (AAIH)?
Guest Links and Resources:
Connect with Sean Khozin on LinkedIn
Visit Braven Partners
Host Links:
Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App
HealthXL: Website | Twitter | Join an Event
Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to:
> Presenting Partner: Amalgam Rx
> Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram
Ep71: Learning from AI: Lessons for Digital Therapeutic Pioneers